期刊
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
卷 31, 期 3, 页码 307-318出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beem.2017.04.013
关键词
thyroid cancer; tyrosine kinase; targeted therapy; MEN; RET; TKI
资金
- NIH [1R01CA197178-01A1R]
- NATIONAL CANCER INSTITUTE [R01CA197178] Funding Source: NIH RePORTER
RET receptor tyrosine kinase acts as a mutated oncogenic driver in several human malignancies and it is over-expressed in other cancers. Small molecule compounds with RET tyrosine kinase inhibitory activity are being investigated for the targeted treatment of these malignancies. Multi-targeted compounds with RET inhibitory concentration in the nanomolar range have entered clinical practice. This review summarizes mechanisms of RET oncogenic activity and properties of new compounds that, at the preclinical stage, have demonstrated promising anti-RET activity. (C) 2017 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据